Alcon pushes ahead with WaveLight merger
This article was originally published in Clinica
Executive Summary
Alcon's proposed acquisition of Erlangen, Germany-based eye correction laser and diagnostic systems developer WaveLight has cleared another hurdle, just days after receiving antitrust approval from the German authorities. WaveLight's board of directors this week gave the thumbs up to Alcon's "very attractive" offer of E15 ($20.23) per share, and recommended that shareholders tendered their shares to the Fort Worth, Texas company. Alcon had originally agreed to pay E10 per share when it announced the proposed acquisition in mid-July (see Clinica No 1265, p 12), but recently upped its offer by E5 to reflect positive trading activity. The tender offer, which was initiated on August 13, will conclude on September 11.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.